This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Endo (ENDP) Stock Declines Despite Q3 Earnings & Revenue Beat
by Zacks Equity Research
Endo (ENDP) tops revenues and earnings expectations in the third quarter and raises its annual view. However, the results from the cellulite treatment trial are disappointing.
Catalyst (CPRX) Reports Q3 Loss as Expected & Pipeline Update
by Zacks Equity Research
Catalyst (CPRX) provides pipeline update and the FDA sets action date of Nov 28, 2018 for its lead pipeline candidate, Firdapse during the third quarter of 2018.
Keryx's (KERX) Loss Narrower Than Expected in Q3, Sales Lag
by Zacks Equity Research
Keryx's (KERX) sole marketed product generates sales of $26.6 million in the third quarter, up 96% from the year-ago quarter.
The Zacks Analyst Blog Highlights: DXP Enterprises, Bristol-Myers Squibb, EnPro Industries, Illumina and NetApp
by Zacks Equity Research
The Zacks Analyst Blog Highlights: DXP Enterprises, Bristol-Myers Squibb, EnPro Industries, Illumina and NetApp
Celldex (CLDX) Q3 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Celldex (CLDX) reports narrower-than-expected loss in Q3. Revenues fall on reduced contract revenues and also miss estimates.
Pharma Stock Roundup: LLY, AZN Report Q3 Earnings, PFE Gets FDA Nod for Cancer Drug
by Zacks Equity Research
Lilly (LLY) and AstraZeneca (AZN) report third-quarter results. Pfizer (PFE) gains FDA approval for a new cancer medicine.
Bristol-Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Bristol-Myers Squibb (BMY) closed the most recent trading day at $52.81, moving -0.34% from the previous trading session.
Horizon Pharma (HZNP) Q3 Earnings & Sales Beat, Shares Rise
by Zacks Equity Research
Shares of Horizon Pharma (HZNP) rise almost 16%, owing to record quarterly sales during the third quarter of 2018.
Immune Design (IMDZ) Posts Narrower-Than-Expected Loss in Q3
by Zacks Equity Research
Immune Design (IMDZ) posts narrower-than-expected loss and misses revenue estimates in the third quarter of 2018. It expects to have cash to fund operations in 2021.
Nektar (NKTR) Q3 Earnings & Sales Beat Estimates, Shares Up
by Zacks Equity Research
Nektar's (NKTR) earnings and sales beat estimates in the third quarter. The company enters oncology clinical collaboration with Pfizer to evaluate NKTR-214 combination therapy.
Alnylam's (ALNY) Q3 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
Alnylam (ALNY) incurs wider-than-expected loss year over year in the third quarter of 2018 and reiterates guidance for the year.
Democrats Hold Edge in House Battle: 5 Great Picks (Revised)
by Swarup Gupta
Drug and defense stocks would hugely benefit from a divided Congress.
Wall Street Likely to Sustain Post-Midterm Rally: 5 Picks
by Nalak Das
Investors' optimism has been revived on risky assets like equities with a divided U.S. Congress.
Mallinckrodt (MNK) Beats on Q3 Earnings Estimates, Ups View
by Zacks Equity Research
Mallinckrodt (MNK) surpasses both earnings and sales estimates in the third quarter of 2018.
Bristol-Myers, Infinity to Test Opdivo Combo for Bladder Cancer
by Zacks Equity Research
Bristol-Myers (BMY) signs a contract with Infinity Pharmaceuticals to evaluate the combination of its Pd-1 inhibitor Opdivo and Infinity's IPI-549 for treating advanced urothelial cancer
Ultragenyx (RARE) Posts Narrower-Than-Expected Loss in Q3
by Zacks Equity Research
Ultragenyx (RARE) submitts regulatory filings in Canada, Brazil and Colombia for Crysvita for the treatment of XLH.
Infinity (INFI) Q3 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Infinity (INFI) beats earnings estimates in the third quarter of 2018. The company revised its outlook for 2018 and expects net loss for 2018 to be $10-$20 million, down from its previous expectation of $35-$45 million.
Beaten-Down Pharma ETFs to Buy Post Q3 Results
by Sweta Killa
Despite strong results, the broad market sell-off took the sheen from the pharma ETFs over the past month. These funds have a Zacks ETF Rank #2 (Buy), suggesting solid entry point on beaten down prices.
BMY vs. AZN: Which Stock Is the Better Value Option?
by Zacks Equity Research
BMY vs. AZN: Which Stock Is the Better Value Option?
Democrats Hold Edge in House Battle: 5 Great Picks
by Swarup Gupta
Drug and defense stocks would hugely benefit from a divided Congress.
Corcept (CORT) Q3 Earnings In Line, Revenues Miss Estimates
by Zacks Equity Research
Corcept (CORT) reports in-line earnings in the third quarter of 2018 and reaffirms its revenue guidance for 2018.
Epizyme (EPZM) Reports Narrower-Than-Expected Loss in Q3
by Zacks Equity Research
Epizyme (EPZM) incurs narrower-than-expected loss in the third quarter of 2018. The company is on track to submit an NDA for tazemetostat in epithelioid sarcoma in the first half of 2019.
What's in the Cards for Nektar (NKTR) This Earnings Season?
by Zacks Equity Research
Nektar Therapeutics (NKTR) will report third-quarter results on Nov 7. Investors are expected to focus on pipeline progress.
The Zacks Analyst Blog Highlights: Newfield Exploration, Amazon.com, Bristol-Myers Squibb, Eaton and CF Industries Holdings
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Newfield Exploration, Amazon.com, Bristol-Myers Squibb, Eaton and CF Industries Holdings
Shire's (SHPG) Earnings, Revenues Miss Estimates in Q3
by Zacks Equity Research
Shire (SHPG) misses earnings and revenue estimates in the third quarter of 2018. The company completes the sale of its Oncology franchise in the quarter.